Company profile · Biotech & medical
StemCyte International
永笙生技股份有限公司 · 4178
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
StemCyte develops cell therapy products and provides public and private cell storage services.[1]
The company's umbilical cord blood-derived hematopoietic progenitor cell product REGENECYTE has received U.S. FDA biologics license application approval for hematopoietic and immune system reconstitution in unrelated donor hematopoietic progenitor cell transplantation procedures.[2]
StemCyte also supplies cell raw materials and conducts clinical trials for indications including post-COVID syndrome and acute ischemic strokes.[3]
Next week's investor conferences, ex-dividend dates and shareholder meetings, only in the email. Every listed Taiwan company reports its November sales by 10 Dec. The free Friday email on 11 Dec has the summary: which supply-chain groups grew and which shrank.
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$33m | +16.0% | +7.6% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-15 to 2026-11-13 | −NT$1m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | StemCyte International, Ltd. |
|---|---|
| Chinese name | 永笙生技股份有限公司 |
| Stock code | 4178 (TWSE) |
| Industry | Biotech & medical |
| Founded | 26 Jun 2013 |
| Listed | 30 Apr 2026 |
| Paid-in capital | NT$2.2bn |
| Chairman | 王嘉宗 |
| President | 路孔明 |
| Headquarters | Rm. 2, 9F., No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) |
| Website | https://stemcytebio.com/ |
| Official business description | 細胞新藥 · 細胞供應 · 細胞服務 |
Facts from MOPS company basic information, retrieved 12 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- 永笙生技 StemCyte · website · retrieved 12 Nov 2026
- 美國FDA核准臍帶血產品 - 永笙生技 · website · retrieved 12 Nov 2026
- Annual report 2025 (English), business scope · annual_report · retrieved 12 Nov 2026
Using it at work? Join the team-plan waiting list
After subscribing, check your inbox (and spam folder) and confirm your subscription. We do this to protect you from spammers.